Status: Not yet recruiting
Entecavir With or Without Pegylated Interferon α-2b in Children Aged 3-6 Years With Immune-Active Chronic Hepatitis B
This study aims to evaluate the efficacy and safety of entecavir monotherapy versus sequential entecavir plus pegylated interferon α-2b in achieving functional cure in immune-active, HBeAg-positive children aged 3-6 years with chronic hepatitis B.
Participants needed: 60
Trial details
Phase: Phase 4Age: 3-6Biological sex: AllType: InterventionalSponsor: Qing-Lei ZengUpdated: Jan 16, 2026
Eligibility criteria
Age between 3 and 6 (more than 3 but less than 7) years; [+5]
Previous antiviral treatment for chronic HBV infection; [+10]